Continuous Positive Airway Pressure as a Potential New Treatment for Cluster Headache

Chronic Disease Clinical Trial

— CPAP  

Official title:

Continuous Positive Airway Pressure as a Potential New Treatment for Cluster Headache - a Randomized Controlled Crossover Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03397563
• Other study ID #: 2017/1491
• Status: Completed
• Phase: N/A
• Start date: January 16, 2018
• Est. completion date: August 21, 2019

Study information

• Verified date: March 2020
• Source: St. Olavs Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Cluster headache is also called suicide headache due to excruciating nocturnal attacks. There are few treatment options available. Inhalation of oxygen has shown to abort the attacks.

Continuous positive airway pressure (CPAP) is a machine used during sleep to treat respiratory failure. Automatic CPAP machines adjust the air pressure through the night to keep the upper airways patent.

Single reports have shown a high prevalence of obstructive sleep apnea in people suffering from cluster headache, and positive effects of CPAP treatment, but no randomized controlled trial has been conducted so far.

If proven effective CPAP would make an affordable treatment option for many patients within the existing healthcare system.

Description:

This is a single center study carried out in collaboration between the neurological, neurophysiological and thoracic departments at St. Olavs Hospital in Trondheim.

Participants will keep sleep and headache diaries in a baseline period of 4 weeks, then receive treatment (CPAP or sham-CPAP at nighttime) during 8 weeks, have a 4 week wash out period followed by a second treatment period of 8 weeks (CPAP or sham-CPAP). Finally there will be follow-up during 1 month.

Throughout the whole study (7 months) participants keep a headache diary. Participants must maintain current preventive and sleep medication regimens during the whole study period, and may use acute medication of choice (sumatriptan, oxygen or other).

Sleep registration in all participants will be done by polysomnography(PSG). An Ultra Wide Band radar/movement sensor device will be used to detect sleep patterns, together with wrist pulse oximetry and wrist actigraphy during PSG and the last week of each treatment period.

Neurophysiologic tests such as temperature and pressure thresholds will be measured before PSG and after each treatment period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: August 21, 2019
• Est. primary completion date: August 21, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Fulfils the diagnostic criteria for chronic cluster headache according to ICHD-3 beta 3.1.2.

• is able to separate cluster headache attacks from other types of headache.

• agrees to maintain current preventive headache and sleep medication regimens (no change in type, frequency, or dose) during the whole study period.

• Signed informed consent.

Exclusion Criteria:

• disorders with contraindications for use of continuous positive airway pressure (e.g. unable to remove the ventilation mask due to a movement disorders).

• Nightly cluster headache attacks

• Pregnancy or planned pregnancy

• having had a change in type, dosage or dose frequency of preventive headache or sleep medications < 1 months prior to inclusion.

• Severe depression or other psychiatric disorder that may interfere with the treatment.

• Abuse of alcohol or illicit drugs.

• Other severe chronic pain conditions

Related Conditions & MeSH terms

• Chronic Disease
• Cluster Headache
• Headache

Intervention

Device:
• Continuous Positive Airway Pressure
standard automatic CPAP machine set on optimal automatic pressure
• sham Continuous Positive Airway Pressure
CPAP machine with pressure set below effective impact, i.e. low pressure of 4 cm H2O and adjustment of the ventilation mask

Locations

Country	Name	City	State
Norway	St Olavs Hospital	Trondheim

Sponsors (2)

Lead Sponsor	Collaborator
St. Olavs Hospital	Norwegian University of Science and Technology

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	change from baseline in number of cluster headache attacks per week at week 9-12		12 weeks
Primary	change from baseline in number of cluster headache attacks per week at week 21-24		24 weeks
Secondary	Change from baseline in the number of nightly cluster attacks per week at week 9-12		12 weeks
Secondary	Change from baseline in the number of nightly cluster attacks per week at week 21-24		24 weeks
Secondary	Change from baseline in cluster headache start time per week at week 9-12		12 weeks
Secondary	Change from baseline in cluster headache start time per week at week 21-24		24 weeks
Secondary	Change from baseline in the number of days with cluster headache per week at week 9-12		12 weeks
Secondary	Change from baseline in the number of days with cluster headache per week at week 21-24		24 weeks
Secondary	Change from baseline in the number of hours with cluster headache per week at week 9-12		12 weeks
Secondary	Change from baseline in the number of hours with cluster headache per week at week 21-24		24 weeks
Secondary	Change from baseline in use of acute treatment per week at week 9-12		12 weeks
Secondary	Change from baseline in use of acute treatment per week at week 21-24		24 weeks
Secondary	Change from baseline in subjective sleep quality in week 12	according to sleep diary	12 weeks
Secondary	Change from baseline in subjective sleep quality in week 24	according to sleep diary	24 weeks
Secondary	Change from the night of PSG registration in apnea-hypopnea index (AHI) during sleep to week 12		12 weeks
Secondary	Change from the night of PSG registration in apnea-hypopnea index (AHI) during sleep to week 24		24 weeks
Secondary	Change from the night of PSG registration in oxygen desaturation index (ODI) during sleep to week 12		12 weeks
Secondary	Change from the night of PSG registration in oxygen desaturation index (ODI) during sleep to week 24		24 weeks
Secondary	Change from baseline in heat/cold pain thresholds at week 12 according to thermal test		12 weeks
Secondary	Change from baseline in pressure pain thresholds at week 12 according to algometry test		12 weeks
Secondary	Change from baseline in heat/cold pain thresholds at week 24 according to thermal test.		24 weeks
Secondary	Change from baseline in pressure pain thresholds at week 24 according to algometry test		24 weeks